Epitope Switching as a Novel Escape Mechanism of HIV to CCR5 Monoclonal Antibodies

被引:5
|
作者
Jekle, Andreas [1 ]
Chhabra, Milloni [1 ]
Lochner, Adriane [1 ]
Meier, Sonja [1 ]
Chow, Eugene [1 ]
Brandt, Michael [2 ]
Sankuratri, Surya [1 ]
Cammack, Nick [1 ]
Heilek, Gabrielle [1 ]
机构
[1] Roche Palo Alto LLC, Palo Alto, CA 94304 USA
[2] Roche Diagnost GmbH, Penzberg, Germany
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; CHEMOKINE RECEPTORS; ANTIVIRAL ACTIVITY; HIGHLY POTENT; GP120; BINDING; TYPE-1; ENTRY; VIRAL ENTRY; INFECTION; INHIBITION; RESISTANCE;
D O I
10.1128/AAC.00841-09
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In passaging experiments, we isolated HIV strains resistant to MAb3952, a chemokine (C-C motif) receptor 5 (CCR5) monoclonal antibody (MAb) that binds to the second extracellular domain (extracellular loop 2 [ECL-2]) of CCR5. MAb3952-resistant viruses remain CCR5-tropic and are cross-resistant to a second ECL-2-specific antibody. Surprisingly, MAb3952-resistant viruses were more susceptible to RoAb13, a CCR5 antibody binding to the N terminus of CCR5. Using CCR5 receptor mutants, we show that MAb3952-resistant virus strains preferentially use the N terminus of CCR5, while the wild-type viruses preferentially use ECL-2. We propose this switch in the CCR5 binding site as a novel mechanism of HIV resistance.
引用
收藏
页码:734 / 741
页数:8
相关论文
共 50 条
  • [1] Monoclonal CCR5 Antibody: A Promising Therapy for HIV
    Zhao, Li
    Lai, Yu
    CURRENT HIV RESEARCH, 2023, 21 (02) : 91 - 98
  • [2] Development of Tetravalent, Bispecific CCR5 Antibodies with Antiviral Activity against CCR5 Monoclonal Antibody-Resistant HIV-1 Strains
    Schanzer, Juergen
    Jekle, Andreas
    Nezu, Junichi
    Lochner, Adriane
    Croasdale, Rebecca
    Dioszegi, Marianna
    Zhang, Jun
    Hoffmann, Eike
    Dormeyer, Wilma
    Stracke, Jan
    Schaefer, Wolfgang
    Ji, Changhua
    Heilek, Gabrielle
    Cammack, Nick
    Brandt, Michael
    Umana, Pablo
    Brinkmann, Ulrich
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (05) : 2369 - 2378
  • [3] HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines
    Colin, Philippe
    Benureau, Yann
    Staropoli, Isabelle
    Wang, Yongjin
    Gonzalez, Nuria
    Alcami, Jose
    Hartley, Oliver
    Brelot, Anne
    Arenzana-Seisdedos, Fernando
    Lagane, Bernard
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (23) : 9475 - 9480
  • [4] Monoclonal CCR5 antibody for treatment of people with HIV infection
    Li, Lun
    Sun, TianTian
    Yang, KeHu
    Zhang, Peng
    Jia, Wen Qin
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (12):
  • [5] CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape
    Huetter, Gero
    Bodor, Josef
    Ledger, Scott
    Boyd, Maureen
    Millington, Michelle
    Tsie, Marlene
    Symonds, Geoff
    VIRUSES-BASEL, 2015, 7 (08): : 4186 - 4203
  • [6] Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection
    Klibanov, Olga M.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (08) : 845 - 859
  • [7] Recent Advances in the Development of Small-molecule CCR5 Inhibitors for HIV
    Liu, Tao
    Weng, Zhiyong
    Dong, Xiaowu
    Hu, Yongzhou
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2010, 10 (13) : 1277 - 1292
  • [8] CCR5 and HIV infection
    Blanpain, C
    Libert, F
    Vassart, G
    Parmentier, M
    RECEPTORS & CHANNELS, 2002, 8 (01) : 19 - 31
  • [9] CRISPR in HIV: dangers of CCR5 deletion
    Rusconi, Stefano
    Giacomelli, Andrea
    FUTURE VIROLOGY, 2020, 15 (04) : 207 - 210
  • [10] A review of CCR5 antibodies against HIV: current and future aspects
    Prathipati, Pavan Kumar
    Mandal, Subhra
    Destache, Christopher J.
    THERAPEUTIC DELIVERY, 2019, 10 (02) : 107 - 112